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Abstract
Mesenchymal stem cells have been demonstrated to ameliorate experimental autoimmune encephalomyelitis (EAE), a
model of multiple sclerosis, prompting clinical trials in multiple sclerosis which are currently ongoing. An important
question is whether this therapeutic effect generalises to other autoimmune neurological diseases. We performed two trials
of efficacy of MSCs in experimental autoimmune neuritis (EAN) in Lewis (LEW/Han MHsd) rats, a model of human
autoimmune inflammatory neuropathies. No differences between the groups were found in clinical, histological or
electrophysiological outcome measures. This was despite the ability of mesenchymal stem cells to inhibit proliferation of
CD4+ T-cells in vitro. Therefore the efficacy of MSCs observed in autoimmune CNS demyelination models do not necessarily
generalise to the treatment of other forms of neurological autoimmunity.
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Introduction
Therapeutic efficacy of early administration of high dose of bone
marrow-derived mesenchymal stem cells (BM-MSCs) has been
reported in the treatment of mouse experimental autoimmune
encephalomyelitis (EAE), a model of multiple sclerosis (MS) [1,2].
Clinical trials based upon the data are now underway in patients
with MS [3,4]. Previous studies suggested that these and other types
of stem cells ameliorate autoimmune-mediated demyelination in the
CNS through regulation of the inflammatory response [2,5]. These
findings raise an important question as to whether BM-MSCs might
be beneficial in other inflammatory demyelinating diseases, such as
Guillain-Barre´ syndrome (GBS) and chronic inflammatory demye-
linating polyneuropathy (CIDP). Here, we tested whether intrave-
nously delivered BM-MSCs were therapeutically beneficial in
experimental autoimmune neuritis (EAN), an autoimmune periph-
eral neuropathy that has served as a model for GBS and CIDP [6,7].
Materials and Methods
Experiment 1: Rat MSC characterisation and T-cell
inhibition assays
Characterised, CD90+/CD452/CD11b2 Lewis rat bone
marrow-derived mesenchymal stem cells (BM-MSCs) were
obtained from Dr Darwin Prockop (kindly provided by the
Tulane Center for Gene Therapy through a grant from NCRR of
the NIH, Grant # P40RR017447). Their mesenchymal potential
was confirmed with standard adipogenic and osteogenic assays
[8,9].
The ability of MSCs to inhibit T-cell proliferation in vitro was
assessed with coculture studies using a myelin oligodendrocyte
glycoprotein-reactive CD4+ rat T-cell line [10].
CD4+ lymphocytes were loaded with the cell division tracking
dye carboxyfluorescein diacetate succinimidyl ester (CFSE Vy-
brant V-12883, Molecular Probes). Coculture studies were
established in 12 well tissue culture plates in RPMI 1640 medium
(Sigma-Aldrich R0883) with 10% fetal calf serum. MSCs were
plated at a density of 100000 cells per well the day prior to
coculture to achieve adherent MSC monolayer culture. CD4+
MOG-reactive T-cells were cocultured with either no MSCs, 1:1
ratio of CD4+ cells:rat MSCs or 1:1 ratio of CD4+cells: human
MSCs. Cells were either unstimulated or stimulated with
recombinant MOG and rat APCs as previously described [10].
After 48 hours of coculture CFSE staining in T-cells was analyzed
by a FACScan flow cytometer (Dako). Proliferation index (defined
as the sum of the cells in all generations divided by the computed
number of parent cells) were calculated using Modfit LT 3.0
(Verity Software) [11]
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EAN Induction and Treatment Protocol
All experiments were licensed under the Animals (Scientific
Procedures) Act 1986 of the UK Home Office. UK Home Office
Project Licence Number: PPL 70/06710. EAN was induced in
Lewis rats, strain LEW/Han MHsd (180–200 g; n = 50) by
immunisation with peripheral bovine myelin and complete
Freund’s adjuvant (1 mg/ml Mycobacterium tuberculosis) [6].
Cells were harvested at passage 9 and resuspended in 1 ml
Hanks Buffered Saline Solution (HBSS) at a concentration of
156106 cells/kg/ml. Animals were randomly assigned into four
groups (n = 10 per group) to receive one of the treatments: i) BM-
MSCs, ii) dermal fibroblasts (obtained by plating Lewis rat-derived
dermal explants onto plastic in serum-containing media, and
included as a cellular control), iii) dead BM-MSCs (killed by
repeated freeze- thaw cycle), or iv) HBSS alone. A further, fifth
control group of treatment-naı¨ve animals (i.e. no injections) was
also included. The treatments were administered under general
anaesthesia as a slow intravenous injection five days after
immunisation in a total volume of 1 ml: all cellular treatments
were at a dose of 156106 cells/kg, in a blinded fashion. In separate
cell tracing experiments, BM-MSCs were labelled with CFSE
using identical cell dosages and treatment protocols to the main
experiment.
EAN scoring – primary and secondary outcome measures
The severity of neurological deficit in EAN was assessed by a
blinded examiner on a ten point scale [6]. Immediately prior to the
termination of the experiment (day 30), a measure of the number
of functioning axons in the spinal roots and sciatic nerve was
obtained electrophysiologically in vivo. The electrophysiological
findings were assessed by a blinded examiner on a five point scale,
where increasing score reflected greater amplitude and increasing
complexity of the compound action potential, indicating increas-
ing numbers of functional axons. The sciatic nerves were removed
and one nerve was post-fixed in Karnovsky’s solution and
processed into resin for high resolution microscopy, and the other
nerve was post-fixed in 3% paraformaldehyde solution, embedded
in OCT and 12 mm thick longitudinal sections were labelled with
anti-ED1 antibodies (Serotec,1:2000; a marker of activated
macrophages). The percentage of myelinated vs. demyelinated
axons was quantified in ten randomly chosen fields within 1 mm
toluidine-blue stained resin cross sections of sciatic nerves (100%
represented a field where no axons were demyelinated). The
number of ED1+ cells was determined by counting the cells in ten
randomly chosen high power fields. In cell tracing experiments,
lymphoid organs and peripheral nerve were removed at day 3 and
7 post BM-MSC injection, fixed in 3% paraformaldehyde and
processed as described above.
Experiment 2: Human MSC characterisation
Highly characterised human MSCs were obtained from Poietics
and their in vitro phenotype (CD90+/CD105+/CD342/CD452)
and mesenchymal differentiation confirmed using standard
protocols [8,9]. Inhibition of rat T-cell proliferation was confirmed
using the same T-cell proliferation assay as described above.
Treatment of EAN with human MSCs
Human MSCs were harvested at passage 9, suspended in HBSS
at a concentration of 256106 MSCs per kg and injected day 7 post
immunisation (n = 10). HBSS alone (no cells) was used as a control
(n = 10). Immunisation and scoring was performed as previously
described. Sciatic nerves were processed for immunohistochemis-
try as described above. 12 mm thick longitudinal sections were
labelled with anti-human antibody human nuclear antigen (1:100;
Chemicon).
Statistical analysis
Analysis of clinical and secondary EAN trial outcomes was
undertaken using one way ANOVA and Kruskal-Wallis test.
Results
Functional characterisation of rat bone marrow-derived
mesenchymal stem cells (i) Inhibition of T-cell
proliferation
Lewis rat-derived CD90+/CD452/CD11b2 mesenchymal
stem cells grew in monolayer culture and their ability to inhibit
T-cell proliferation was assessed by coculture with myelin-reactive
CD4+ T-cells.
CFSE proliferation assays of rMOG-stimulated CD4+ T cells
demonstrated that addition of mesenchymal stem cells (both rat
and human in a 1:1 ratio with CD4+ cells) reduced the
proliferation index of CD4+ cells (Figure 1A, representative FACS
plots). The proliferation index of MOG-stimulated CD4+ cells was
7.19+/2 0.3 (n = 5, figure 1B) in the absence of MSCs. The
addition of Lewis rat MSCs reduced the proliferation index to
1.4+/20.1 (n = 3, figure 1B). The addition of human MSCs to the
coculture also reduced the proliferation index to 1.4+/20.1 (n = 3,
figure 1B). This effect was dose-dependent (not shown).
Functional characterisation of rat bone marrow-derived
mesenchymal stem cells (ii) Mesenchymal differentiation
Lewis rat-derived MSCs differentiated appropriately into
adipocytes and osteocytes. Functional differentiation was con-
firmed by oil red O staining and alizarin red staining, respectively
(Fig. 2 A–B).
No evidence of efficacy of rat MSCs in the treatment of
EAN
Next, we treated animals with EAN by administrating BM-
MSCs or control treatments. No adverse effects related to cell
administration were observed in any of the treated animals. No
significant differences between the groups were found with respect
to time of disease onset (p = 0.76, Kruskal-Wallis test), peak
severity of disease (p = 0.3, Kruskal-Wallis test), overall disease
severity or magnitude of residual neurological deficit (p = 0.7 and
p = 0.41, respectively, Kruskal-Wallis test and one-way ANOVA)
(Table 1, Figure 2C). Furthermore, no significant differences were
observed in a range of electrophysiological measures of axonal
conduction resulting from stimulation of the spinal roots or sciatic
nerves undertaken at the termination of the experiment (p = 0.88,
Kruskal-Wallis test. Table 1).
Similarly, quantitative assessment of demyelination (Figure 2D,
Table 1) and macrophage infiltration of sciatic nerves (Table 1)
showed no significant differences between the groups (p = 0.34,
p = 0.71 respectively, one-way ANOVA).
Labelled BM-MSCs were histologically detected in bone
marrow, lungs, spleen and lymph nodes, but not peripheral
nerves, three and seven days post-administration (Figure 2E–H).
Characterisation of human bone marrow-derived
mesenchymal stem cells
Human bone marrow-derived MSCs grew as confluent plastic
adherent monolayers and FACS analysis confirmed the following
cell surface marker phenotype: CD90+/CD105+/CD342/
CD452 (figure 3A). Human MSCs differentiated into adipocytes,
MSCs Are not Effective in Autoimmune Neuropathy
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Figure 1. Mesenchymal stem cells derived from rat and human inhibit proliferation of myelin-reactive CD4+ T-cells in vitro. (A) CFSE
proliferation assays, gated on CD4+ myelin reactive T-cells. Addition of a monoclonal myelin stimulus (MOG) leads to proliferation of T-cells, which is
abolished by 1:1 coculture with rat MSCs (rMSCs) and human MSCs (hMSCs). Representative FACS plots shown. (B) Coculture with rat mesenchymal
stem cells and human mesenchymal stem cells leads to reduction in proliferation index of MOG-reactive CD4+ cells. (7.19+/20.3 in absence of MSCs
(n = 5), 1.4+/20.1 with rat MSC coculture (n = 3), 1.4+/20.1 with human MSC coculture (n = 3).
doi:10.1371/journal.pone.0030708.g001
Figure 2. Lewis rat-derived MSCs do not improve clinical, electrophysiological or histological outcomes in experimental
autoimmune neuritis. (A, B) Apidogenic and osteogenic potential of CD90+/CD452/CD11b2 Lewis BM-MSCs. Adipogenesis confirmed by Oil red
O staining and osteogenesis confirmed by Alizarin Red staining. (C) Clinical course of EAN following various treatments. HBSS =Hank’s buffered saline
solution vehicle alone, BM-MSCs= 156106 bone marrow mesenchymal stem cells/kg, DF = 156106 dermal fibroblasts/kg, dead MSCs= 156106 dead
bone marrow mesenchymal stem cells/kg, no treatment = no injection or anaesthesia. No significant differences in disease onset, severity or residual
deficit were observed between groups. (D) Representative semithin sections from experimental groups. Inflammatory demyelination and axonal loss
were observed in all groups. No histo-pathological differences were found between the treatment groups, as analysed in toluidine blue-stained
micrographs of transverse sections (1 mm) through the sciatic nerves from animals in each group. (E–H) In cell tracing experiments, CFSE-labelled BM-
MSCs were identified in bone marrow and lymphoid organs seven days after cell delivery (Hoechst – Blue; CFSE - Green; F & H show detail from E & G).
doi:10.1371/journal.pone.0030708.g002
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osteocytes and chondrocytes in response to standard differentia-
tion protocols (figure 3B,C and D) and inhibited rat T-cell
proliferation to monoclonal stimuli. (figure 1A).
No evidence of efficacy of human MSCs in the treatment
of EAN
A second trial using human MSCs in the treatment of EAN was
performed. A higher dose of 256106 cells/kg delivered at a later
timepoint (day 7 post-immunisation). No significant difference was
observed between MSC-treated and vehicle-only groups in both
peak or cumulative disease scores (no significant difference,
Kruskal-Wallis test, Figure 2E). No evidence of human mesen-
chymal stem cell engraftment in peripheral nerves was observed.
Discussion
Previous reports have demonstrated a striking therapeutic
efficacy of BM-MSCs when delivered early in the time course of
EAE in mice [1,2]. By contrast, we have shown that rat and
human BM-MSCs, delivered intravenously at a similar time, do
not lead to any discernable neurological, neurophysiological or
histopathological improvement of EAN in Lewis rats, despite their
mesenchymal potential and ability to inhibit T-cell proliferation in
vitro.
It is unclear why rodent and human BM-MSCs have profound
efficacy in EAE but lack any effect in EAN when delivered at a
similar stage of disease. These findings may reflect interspecies
differences in immune response to antigen and also the distinct
nature of the respective antigens between central (EAE) and
peripheral (EAN) nervous system components [1,7]. It is thus
possible that the immunomodulatory effect of BM-MSCs is
specific to mouse EAE while lacking efficacy in other autoimmune
neurological disorders with similar immunopathogenesis but
different target antigens. Another explanation for the discrepancy
between the effect of BM-MSCs in EAE in mice and EAN in rat, is
the difference in cell doses used in the studies. We have used cell
Table 1. Outcome measures between BM-MSC treatment groups and control groups.
BM-MSCs HBSS alone
Dermal
fibroblasts
Dead
BM-MSCs No treatment
Significance
(p)
Median day of disease onset (range) 12 (10–16) 12 (10–13) 12 (9–13) 12.5 (10–14) 12 (10–13) 0.76*
Median peak motor score (range) 5.5 (4–7) 5.5 (4–7) 5 (4–6) 5 (4–6) 6 (4–9) 0.3*
Median terminal motor score (range) 3 (0–5) 3 (0–4) 3.5 (2–5) 2 (0–5) 4 (2–6) 0.41*
Mean cumulative motor score (SD) 65.3 (18) 64.3 (17.6) 69.6 (13.3) 64.9 (21.9) 76.9 (12.4) 0.71
Electrophysiology: ankle-foot
median response score (range)
2/1 (0–4)/(0–4) 1/2 (0–3)/(0–4) 1/2 (0–3)/(0–4) 2/2 (0–4)/(0–2) 0/2 (0–2)/(0–3) 0.88*
Mean count of ED1+ cells
per HPF (SD)
194 (81) 192 (68) 199 (84) 204 (86) 238 (63) 0.711
Mean % of myelinated axons
per HPF (SD)
25 (27) 27 (20) 27 (22) 31 (24) 9 (5) 0.341
SD – standard deviation;
*Kruskal-Wallis test;
1one way ANOVA, Tukey post-test;
HPF – high power field;
doi:10.1371/journal.pone.0030708.t001
Figure 3. Human MSCs do not exert clinical effect in experimental autoimmune neuritis. (A) FACS profile of human MSCs confirms a
CD90+/CD105+/CD342/CD452 phenotype. (B) Human MSCs grow as confluent monolayers on tissue culture plastic and display mesenchymal
differentiation (C) Osteogenesis: Alizarin red =orange, (D) Adipogenesis: Oil red O= red. (E) Human MSCs, delivered day 7 post immunisation at a
dose of 256106 MSC/kg in 1 ml HBSS do not lead to a significantly different clinical outcome when compared with HBSS injection alone.
doi:10.1371/journal.pone.0030708.g003
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doses (per kg) at the lower end of those used in murine EAE
studies. In published EAE and EAN trials the cell dosage is at least
one order of magnitude higher than doses used routinely in clinical
practice in humans [1,2,12,13]. In the case of both rodent and
human studies, an upper limit of cell dosage is placed by the limits
of timing of culture and cellular load that can be safely delivered
without adverse effects [13].
The in vitro inhibition of T-cell proliferation has been suggested
to represent an in vitro model of the immunosuppressive properties
of BM-MSCs [21], the proposed mechanism by which BM-MSCs
ameliorate EAE [1,2]. However, we and others have found that
the in vitro immunosuppression is not specific to BM-MSCs [17].
For instance, we have found that a wide variety of plastic adherent
cells, including dermal fibroblasts and an epithelial cell line
derived from monkey kidney (Vero cells), exhibit such an effect
(unpublished data). This cellular nonspecificity highlights the need
to include cellular control groups (such as dermal fibroblasts)
during in vivo trials.
Our experiments were primarily designed to see if MSC
administration could prevent the development of EAN when given
early in disease course. There is clear evidence of a gradient of
response of experimental autoimmunity when treated with MSCs,
suggesting that early treatment provides a maximal therapeutic
response, which reduces significantly over time [2,5]. For example
in the treatment of EAE with MSCs there is only a very minor
effect on scores of disease severity when MSCs are delivered at first
clinical manifestation of disease, although earlier administration in
the presymptomatic phase leads to very significant disease
amelioration [2]. This time window for treatment is observed
with many other immunosuppressive treatments in the context of
experimental autoimmunity [20]. We therefore administered
MSC treatment at two distinct timepoints during this early phase
of immunopathogenesis where an immunosuppressive therapy
might be anticipated to be maximally effective [19,20]. Our
experiments do not completely rule out the possibility that later
(postsymptomatic) treatment with MSCs might lead to improve-
ment by an alternative effects, such as engraftment of MSCs in the
peripheral nerve, where they might mediate either neuroprotective
or local anti-inflammatory effects. Such an immunomodulatory
effect (within the target organ), has been observed in a model of
EAE [18]. However, although we found evidence that MSCs
migrated to peripheral lymphoid organs and bone marrow we
found no evidence in either experiment to suggest that MSCs
migrate to the peripheral nerve. It is therefore unlikely that MSCs
exert a local immunosuppressive effect within the peripheral
nerve.
It has been suggested that BM-MSCs may have a therapeutic
role in a range of autoimmune diseases, including vasculitis, liver
diseases, diabetes, inflammatory bowel disease and inflammatory
neuropathies [14,15,16]. Our findings illustrate the importance of
careful validation and experimental testing before the findings of
pre-clinical studies in animal models are extrapolated to both
larger species and different diseases, regardless of similarities in
their immunopathogenesis.
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